欧洲精品一区二区三区_欧美性性性性_国产一区二区免费在线播放_日日噜噜噜噜人人爽日本精品_无套中出丰满人妻无码_国产偷窥熟女精品视频大全

瑞士輝凌制藥Ferring Pharmaceuticals
輝凌集團(tuán)于1950年由Frederik Paulsen博士創(chuàng)辦，是世界上首家生產(chǎn)人工合成肽的公司之一, 并在不同的治療領(lǐng)域上，包括泌尿科、生殖醫(yī)學(xué)、婦產(chǎn)科、胃腸道疾病和內(nèi)分泌系統(tǒng)疾病等，開(kāi)發(fā)各類創(chuàng)新藥品。

輝凌集團(tuán)的總部設(shè)于瑞士，在瑞士、瑞典、丹麥、德國(guó)和捷克共和國(guó)均設(shè)有生產(chǎn)廠房，研發(fā)中心則在英國(guó)和美國(guó)，分支機(jī)構(gòu)遍布世界40多個(gè)國(guó)家。過(guò)去的20年間，輝凌集團(tuán)保持每年約20%的增長(zhǎng)。

于九十年代初，F(xiàn)ERRING在香港成立輝凌制藥有限公司，作為亞太區(qū)總部。在這十?dāng)?shù)年，成功將產(chǎn)品引進(jìn)亞洲區(qū)內(nèi)多主要市場(chǎng)，令更多的病人獲得最新及最適當(dāng)?shù)乃幬镏委煛?/p>

輝凌中國(guó)于1996年成立， 令輝凌集團(tuán)成為其中一家最早獲準(zhǔn)在國(guó)內(nèi)設(shè)立全資擁有企業(yè)的外國(guó)公司。為配合輝凌集團(tuán)的發(fā)展計(jì)劃，輝凌中國(guó)于2003年在廣東省中山港國(guó)家健康基地興建了一所占地20,000平方尺的高科技生產(chǎn)廠房，總投資額為一千四百伍拾萬(wàn)美元，廠房于2005年3月開(kāi)幕后，成為輝凌集團(tuán)在亞太區(qū)第一家生產(chǎn)廠房。

一直以來(lái)，F(xiàn)ERRING與很多大學(xué)、醫(yī)療機(jī)構(gòu)和其他研究所都有著緊密聯(lián)系，共同進(jìn)行研究工作。我們深信，以我們?nèi)諠u擴(kuò)展的網(wǎng)絡(luò)，F(xiàn)ERRING的產(chǎn)品將令更多病人受惠，從而實(shí)現(xiàn)我們的承諾：輝凌制藥 — 以科學(xué)造福人類。

總部位于瑞士的Ferring醫(yī)藥在全球范圍內(nèi)設(shè)銷售和生產(chǎn)點(diǎn)，在哥本哈根還有一個(gè)大型研發(fā)中心。全球有超過(guò)2700名員工，并以縮氨酸產(chǎn)品聞名于世。

Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of infertility, obstetrics, urology, gastroenterology, endocrinology and osteoarthritis.

The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.

The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.

Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.

Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3500 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.

Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.

Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.